Quality-Data Code Submission Error Report 2nd Quarter 2010 Physician Quality Reporting Initiative

Report Date: 09/20/2010

This summary is provided to assist eligible professionals and their staff in interpreting the Quality-Data Code Submission Error Report by Measure. Please note that this report is based on the number of valid quality-data codes (QDCs) submitted by measure and reasons why a submission is considered invalid. This report does not include the number of claims for which an expected QDC was not submitted on an eligible claim.

Column Definitions:

- Total QDCs Reported Number of QDC submissions for a measure whether or not the QDC submission was valid and appropriate for a measure.
- Total Valid QDCs Reported Number of valid and appropriate QDC submissions for a measure.
- % Valid Percentage of Total Valid QDCs Reported divided by Total QDCs Reported.
- Total QDCs Reported on Eligible Cases Number of valid or invalid QDCs reported on eligible cases meeting the measure's denominator criteria.
- Patient Age Mismatch Patient did not meet age requirements for the measure.
- Patient Gender Mismatch Patient did not meet gender requirement for the measure.
- Incorrect HCPCS Incorrect HCPCS code for the measure Patient claim did not meet denominator eligibility per measure specifications.
- Incorrect Diagnosis Incorrect diagnosis code on claim Patient claim did not meet denominator eligibility per measure specifications.
- Incorrect Diagnosis and HCPCS Combination of incorrect HCPCS code and incorrect diagnosis code on claim Patient claim did not meet denominator eligibility per measure specifications.
- Only QDC on Claim Patient claim missing a qualifying denominator code (all line items contained only QDCs).
- Only QDC and Incorrect Diagnosis Combination of missing qualifying denominator code and qualifying diagnosis code on the claim.
- Resubmitted QDCs Submissions invalid due to resubmission of claims simply for the purpose of adding QDCs.
- Unattributed/No NPI Submissions where the rendering NPI was missing.

How to Read the Quality-Data Code Submission Error Report by Measure:

Using Measure #47-Advance Care Plan as an example, we find the following information as we read across each column:

379,781 QDC submissions were received for this measure, 327,136 of which were considered valid. Therefore, the Valid Submission Rate is 86.14%. The rest of the columns explain reasons for invalid submissions for measure #47. We see that 17,210 (4.53%) submissions did not match the measure's age parameters; there is no gender parameter for this measure; 35,024 (9.22%) submissions were for patient encounters that are not listed in the denominator; this measure applies to all Medicare Part B beneficiaries regardless of diagnosis; 4,155 (1.09%) submissions showed only the numerator component (QDCs) on the claim and the denominator component (HCPCS) were not on the claim nor on any other related claim for the same beneficiary, date-of-service, NPI/TIN. There were no submissions with a combination of QDC-only and diagnosis mismatch and no QDC resubmissions for this measure. There were also no submissions which lacked an NPI in the rendering provider ID field on the claim.

Analysis Findings Include:

1. The top 5 measures with the highest percentage of valid QDCs codes submitted were:

#147 Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintingraphy (97.44%),

#177 Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity (97.22%),

#179 Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis (97.22%),

#173 Preventive Care and Screening: Unhealthy Alcohol Use - Screening (97.05%), and

#146 Radiology: Inappropriate Use of "Probably Benign" Assessment Category in Mammography Screening (96.87%).

2. The 5 measures with the lowest percentage of Valid QDCs submitted (with at least 1 eligible instance) were:

#66 Appropriate Testing for Children with Pharyngitis (0.17%),

#188 Referral for Otologic Evaluation for Patients with Congenital or Traumatic Deformity of the Ear (0.21%),

#65 URI: Appropriate Treatment for Children (0.25%),

#46 Medication Reconciliation: Reconciliation After Discharge from an Inpatient Facility (1.57%), and

#157 Thoracic Surgery: Recording of Clinical Stage for Lung Cancer and Esophageal Cancer Resection (1.59%),

- 3. The measures that are in the top 25% of all measures on Total QDCs Reported and in the bottom 25% for percentage of Valid QDCs are: #20 Perioperative Care: Timing of Antibiotic Prophylaxis Ordering Physician and #55 ECG Performed for Syncope. Both of these measures share QDCs with other current measures.
- 4. The top 5 measures with the highest percentage of claims with QDCs only (no denominator-eligible codes) were:

#134 Screening for Clinical Depression (9.34%),

#112 Screening Mammography (5.77%),

#155 Falls: Plan of Care (4.36%),

#46 Medication Reconciliation: Reconciliation After Discharge from an Inpatient Facility (4.00%), and

#181 Elder Maltreatment Screen and Follow-Up Plan (3.86%).

5. The 5 measures with the highest rate of Diagnosis errors were:

#40 Osteoporosis: Management Following Fracture (91.09%),

#122 CKD: Blood Pressure Management (64.09%),

#55 ECG Performed for Syncope (58.14%),

#189 Referral for Otologic Evaluation for Patients with History of Active Drainage From the Ear Within the Previous 90 Days (46.67%), and #121 CKD: Laboratory Testing (Calcium, Phosphorus, iPTH and Lipid Profile) (40.47%).

6. The top 5 measures with the highest rate of HCPCS errors were:

#20 Perioperative Care: Timing of Antibiotic Prophylaxis - Ordering Physician (91.40%),

#45 Perioperative Care: Discontinuation of Prophylactic Antibiotics (68.23%),

#181 Elder Maltreatment Screen and Follow-Up Plan (46.42%),

#44 Preoperative Beta-blocker in Patients with Isolated CABG Surgery (38.47%), and

#43 Use of IMA in CABG Surgery (37.17%).

7. The 5 measures with the highest rate of patient gender errors were:

#48 Assessment of Presence or Absence of UI in Women Aged 65 Years and Older (3.99%),

#49 Characterization of UI in Women Aged 65 Years and Older (3.43%),

#50 Plan of Care for UI in Women Aged 65 Years and Older (3.33%),

#39 Osteoporosis: Screening or Therapy for Women Aged 65 Years and Older (3.03%), and

#112 Screening Mammography (1.58%).

8. Overall, the percentage of reported instances with missing NPIs was 0.00%.

Please note: Modifications were made to the analytic code that identifies and selects qualifying HCPCS codes for some of the procedure-type measures. The counts of Reporting Denominator and Valid QDCs Reported for those measures decreased from the 1st quarter report to the 2nd quarter report. The measures affected were numbers 10, 21, 22, 99, 100, 146, 157, 172, and 185.

	ODC Su	bmission Attempt							Denomi	nator Misi	match ^c											
	QDC 3u	Total Valid	3		Patien	t Age	Patient	Gender			Denomi	nator misi		and HCPCS			Incorrect D	X and Only				
	Total QDCs	QDCs		Total QDCs Reported	Misma		Mism		Incorrec	t HCPCS	Incorrec	ct DX		orrect	Only QDC o	on Claim	QI		Resubmitt	ted QDCsf	Unattribute	d (No NPI) ⁹
Topic Measure	Reported	Reported ^b	% Valid	on Eligible Cases	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%
Advance Care Plan #47 Advance Care Plan	379.781	327,136	86.14%	340.602	17.210	4.53%		0.00%	35.024	9,22%	0	0.00%		0.00%	4.155	1.09%	0	0.00%	0	0.00%	0	0.00%
#47 Advance Care Plan Anesthesia	3/9,/61	327,130	00.14%	340,002	17,210	4.53%	·	0.00%	35,024	9.22%	U	0.00%	U	0.00%	4,100	1.09%	U	0.00%	U	0.00%	U	0.00%
#193 Perioperative Temperature Management	541,116	504,489	93.23%	518,454	C	0.00%	C	0.00%	20,653	3.82%	0	0.00%	0	0.00%	2,009	0.37%	0	0.00%	0	0.00%	1	0.00%
Arthritis-Osteoarthritis															,,,,,							
#109 Patients with OA with an Assessment of Pain and Function	37,018	30,934	83.56%	30,938	0	0.00%	0	0.00%	17	0.05%	3,417	9.23%	823	2.00%	172	0.46%	177	0.48%	0	0.00%	0	0.00%
#142 Osteoarthritis (OA): Assessment for Use of Anti-Inflammatory or	00.000	00.054	70.000/	00.057		0.000/		0.000/	40	0.040/	7.040	04 700/		4 000/	400	0.500/	204	0.000/		0.000/		0.000/
Analgesic Over-the-Counter (OTC) Medications Arthritis-Rheumatoid	33,662	23,854	70.86%	23,857	U	0.00%	U	0.00%	13	0.04%	7,313	21.72%	376	1.00%	169	0.50%	291	0.86%	0	0.00%	0	0.00%
#108 DMARD Therapy in Rheumatoid Arthritis	21,164	20,159	95.25%	20,177	C	0.00%	C	0.00%	212	1.00%	710	3.35%	13	0.00%	37	0.17%	51	0.24%	10	0.05%	0	0.00%
#176 Rheumatoid Arthritis (RA): Tuberculosis Screening	5,384	4,831	89.73%	5,260		0.00%		0.00%	41	0.76%	64	1.19%	3	0.00%	6	0.11%	6	0.11%	10	0.19%	0	0.00%
#177 Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity	5,867	5,704	97.22%	5,705		0.00%		0.00%	29	0.49%	118	2.01%	5	0.00%	7	0.12%	9	0.15%	0	0.00%	0	0.00%
#178 Rheumatoid Arthritis (RA): Functional Status Assessment	6,895	6,666	96.68%	6,668		0.00%		0.00%	36	0.52%	178	2.58%	3	0.00%	8	0.12%	10	0.15%	0	0.00%	0	0.00%
#179 Rheumatoid Arthritis (RA): Assessment and Classification of Disease	·																					
Prognosis	4,169	4,053	97.22%	4,064	0	0.00%	0	0.00%	20	0.48%	77	1.85%	2	0.00%	6	0.14%	4	0.10%	0	0.00%	0	0.00%
#180 Rheumatoid Arthritis (RA): Glucocorticoid Management	4,111	3,948	96.04%	4,014	C	0.00%	C	0.00%	24	0.58%	62	1.51%	4	0.00%	7	0.17%	4	0.10%	0	0.00%	0	0.00%
	2.460	397	16.14%	437	4.004	80.65%		0.00%	- 44	0.57%	23	0.93%	1 895	77.00%	- 1	0.04%	91	3.70%	0	0.00%	0	0.00%
#53 Pharmacologic Therapy #64 Asthma Assessment	1,693	232		232	1,964	85.23%	0	0.00%	7	0.57%	10	0.59%	1,895	81.00%	0	0.04%	71	4.19%	0	0.00%	0	0.00%
Audiology	1,000	202		202	., 110	55.2576		2.2270		270	.0	2.2370	.,274	22270	Ü	2.2370		570	Ů	5.5570	Ů	2.2370
#188 Referral for Otologic Evaluation for Patients with Congenital or																						
Traumatic Deformity of the Ear	467	1	0.21%	1	C	0.00%	c	0.00%	1	0.21%	5	1.07%	458	98.00%	0	0.00%	3	0.64%	0	0.00%	0	0.00%
#189 Referral for Otologic Evaluation for Patients with History of Active		İ																				
Drainage From the Ear Within the Previous 90 Days	30	7	23.33%	8	0	0.00%	0	0.00%	0	0.00%	14	46.67%	8	27.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%
#190 Referral for Otologic Evaluation for Patients with a History of Sudden			00.000/	20.4		0.000/		0.000/	_	4.040/		4.000/		4 000/		4.000/		0.000/		0.000/		0.000/
or Rapidly Progressive Hearing Loss Breast Cancer	311	288	92.60%	294	C	0.00%	C	0.00%	5	1.61%	6	1.93%	2	1.00%	4	1.29%	1	0.32%	0	0.00%	0	0.00%
#71 Hormonal Therapy for Stage IC-III ER/PR Positive Breast Cancer	44.721	40.133	89.74%	43.183	0	0.00%	193	0.43%	437	0.98%	722	1.61%	237	1.00%	134	0.30%	25	0.06%	0	0.00%	0	0.00%
#99 Breast Cancer Patients with a pT and pN Category and Histologic	,	,		,							-											0.007.0
Grade	25,247	13,568	53.74%	13,571	0	0.00%	0	0.00%	522	2.07%	9,488	37.58%	1,447	6.00%	111	0.44%	353	1.40%	0	0.00%	0	0.00%
#112 Screening Mammography	84,603	54,647	64.59%	54,674	24,608	29.09%	1,334	1.58%	25,045	29.60%	0	0.00%	0	0.00%	4,884	5.77%	0	0.00%	0	0.00%	0	0.00%
Bronchitis	000		00.500/	00	000	70.000/		0.000/		0.750/	40	4.700/	000	74.000/		0.050/		4.000/		0.000/		0.000/
#116 Inappropriate Antibiotic Treatment for Adults	399	90	22.56%	90	282	70.68%	C	0.00%	3	0.75%	19	4.76%	283	71.00%	1	0.25%	4	1.00%	0	0.00%	0	0.00%
#6 Oral Antiplatelet Therapy Prescribed for Patients with CAD	513,320	477.208	92.97%	477,208	1	0.00%	0	0.00%	8,407	1.64%	24.089	4 69%	1.166	0.00%	2.087	0.41%	1,343	0.26%	0	0.00%	0	0.00%
Cataracts	0.0,020	111,200	02.0170	117,200		0.007		0.0070	0,101	1.0470	21,000	4.0070	1,100	0.0070	2,001	0.1170	1,010	0.2070	Ü	0.007.0	Ü	0.0070
#139 Cataracts: Comprehensive Preoperative Assessment for Cataract																						
Surgery with Intraocular Lens (IOL) Placement	260,244	249,299	95.79%	249,340	C	0.00%	C	0.00%	9,273	3.56%	0	0.00%	0	0.00%	1,631	0.63%	0	0.00%	0	0.00%	2	0.00%
Catheter-Related Bloodstream Infections (CRBSI)																						
#76 Prevention of CRBSI - Central Venous Catheter Insertion Protocol	99,796	88,123	88.30%	88,123	C	0.00%	0	0.00%	11,144	11.17%	0	0.00%	0	0.00%	529	0.53%	0	0.00%	0	0.00%	1	0.00%
Chest Pain	005 000	400.070	70.000/	400.000	0.044	4.000/		0.000/	47.000	0.000/	440.044	00.000/	40.040	0.000/	4.045	0.040/	0.445	0.000/		0.000/		0.000/
#54 ECG Performed for Non-Traumatic Chest Pain Chiropractic Care	665,833	486,276	73.03%	486,280	8,614	1.29%	· ·	0.00%	17,338	2.60%	146,611	22.02%	13,246	2.00%	1,615	0.24%	2,115	0.32%	U	0.00%	2	0.00%
#182 Functional Outcome Assessment in Chiropractic Care	29,817	28,178	94.50%	28,178		0.00%		0.00%	1,434	4.81%	0	0.00%	0	0.00%	205	0.69%	0	0.00%	0	0.00%	- 1	0.00%
Chronic Kidney Disease (CKD)	29,017	20,170	94.0076	20,170		0.00%		0.00%	1,434	4.01/0	U	0.0076	0	0.00%	200	0.0976	U	0.00%	U	0.00%	'	0.00%
#121 Laboratory Testing (Calcium, Phosphorus, iPTH and Lipid Profile)	11,606	6.593	56.81%	6,593		0.00%		0.00%	123	1.06%	4.697	40.47%	98	1.00%	52	0.45%	804	6.93%	0	0.00%	0	0.00%
#122 Blood Pressure Management	65,580	12,561	19.15%	13,740	0	0.00%	0	0.00%	9	0.01%	42,030	64.09%	4,113	6.00%	479	0.73%	1,781	2.72%	0	0.00%	0	0.00%
#123 Plan of Care: Elevated Hemoglobin for Patients Receiving ESAs	18,124	8,494	46.87%	9,262	4	0.02%	0	0.00%	125	0.69%	3,589	19.80%	5,005	28.00%	39	0.22%	853	4.71%	0	0.00%	0	0.00%
#135 Chronic Kidney Disease (CKD): Influenza Immunization	15,588	3,409	21.87%	3,409	C	0.00%	C	0.00%	40	0.26%	3,285	21.07%	8,763	56.00%	12	0.08%	859	5.51%	0	0.00%	0	0.00%
#153 Chronic Kidney Disease (CKD): Referral for Arteriovenous (AV)																						
Fistula	7,731	5,037	65.15%	5,037	C	0.00%	C	0.00%	73	0.94%	1,992	25.77%	561	7.00%	31	0.40%	789	10.21%	0	0.00%	0	0.00%
Chronic Obstructive Pulmonary Disease (COPD)	54.007					0.000/														0.000/		
#51 Spirometry Evaluation #52 Bronchodilator Therapy	54,397 45,967	49,164 36,164	90.38% 78.67%	49,164 41.839	0	0.00%	0	0.00%	696 604	1.28% 1.31%	4,128 3,093	7.59% 6.73%	150 146	0.00%	203 245	0.37%	391 203		0	0.00%	2	0.00%
Colon Cancer	45,507	30,104	70.0770	41,000		0.0070		0.0076	004	1.5170	3,033	0.7370	140	0.0076	240	0.5570	203	0.4470	Ü	0.0070	-	0.0070
#72 Chemotherapy for Stage III	13,122	11,691	89.09%	12,287	C	0.00%	C	0.00%	127	0.97%	663	5.05%	19	0.00%	26	0.20%	7	0.05%	0	0.00%	0	0.00%
Colorectal Cancer (CRC)																						
#100 CRC Patients with a pT and pN Category and Histologic Grade	24,152	8,568	35.48%	8,568		0.00%	C	0.00%	387	1.60%	2,782	11.52%	11,920	49.00%	79	0.33%	514		0	0.00%	0	0.00%
#113 CRC Screening	217,570	154,963	71.22%	155,042	57,119	26.25%		0.00%	58,512	26.89%	0	0.00%	0	0.00%	4,016	1.85%	0	0.00%	0	0.00%	0	0.00%
Coronary Artery Bypass Graft (CABG) #43 Use of IMA in CABG Surgery	14.665	9.070	61.85%	9.070	-	0.00%	-	0.00%	5.451	37.17%	n	0.00%	n	0.00%	144	0.98%	n	0.00%	n	0.00%	n	0.00%
#44 Preoperative Beta-blocker in Patients with Isolated CABG Surgery	10,271	6.217	60.53%	6.217	-	0.00%	-	0.00%	3,451	38.47%	0	0.00%	-	0.00%	103	1.00%		0.00%	0	0.00%	0	0.00%
Depression	10,271	0,217	00.53%	6,217	U	0.00%	U	0.00%	3,951	30.41%	U	0.00%	0	0.00%	103	1.00%	U	0.00%	U	0.00%	U	0.00%
#9 Antidepressant Meds During Acute Phase for Patients with New Episode	11,079	7,685	69.37%	7.685	n	0.00%		0.00%	802	7.24%	1.748	15.78%	491	4.00%	300	2.71%	173	1.56%	n	0.00%	n	0.00%
#106 Patients who have MD Disorder who meet DSM IV Criteria	6,697	3,991	59.59%	3,991	0	0.00%	0	0.00%	342	5.11%	1,877	28.03%	170	3.00%	183	2.73%	253	3.78%	0	0.00%	0	0.00%
#107 Patients who have MD Disorder who are Assessed for Suicide Risks	17,091	10,778	63.06%	10,778	0	0.00%	0	0.00%	21	0.12%	3,368	19.71%	233		503	2.94%	475	2.78%	0	0.00%	0	0.00%
	.7,001		22.2570	70,170				/0			2,500				200			2370	<u> </u>	2.2270	<u>~</u>	2.2370

^a For each measure, the total # of instances where an TIN/NPI combination submitted a QDC for that measure.

Note: MCMP and PGP pilot program participants are excluded from these reports (based on the most recent pilot participant list from ORDI).

Note: Individuals participating in GPRO are excluded from these reports.

^b For each measure, the # of instances where an TIN/NPI combination submitted a valid QDC for that measure.

 $^{^{\}circ}$ The # of occurrences of QDC reporting where the QDC does not match the denominator requirements for the measure.

^d The # of occurrences of a QDC reporting where the QDC does not match the age requirements for the measure.

° The # of occurrences of a QDC reporting where the QDC does not match the gender requirements for the measure.

The # of occurrences of a QDC reporting where the QDC was received on a claim that was resubmitted for the purpose of adding QDCs.

g The # of occurrences where a valid NPI is not present.

	QDC Submission Attempts										Denomi	nator Misn										
		Total Valid			Patient	Patient Age		Patient Gender					Both DX a	nd HCPCS			Incorrect D	X and Only				
	Total QDCs	QDCs		Total QDCs Reported	Misma	tchd	Misma	atch ^e	Incorrect	HCPCS	Incorrec	ct DX	Inco		Only QDC	on Claim	QI		Resubmit	ted QDCsf	Unattributed	I (No NPI)9
Topic Measure	Reported	Reported ^b	% Valid	on Eligible Cases	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%
Diabetes				J																		
#1 Hemoglobin A1c Poor Control	324,953	251,399	77.36%	252,127	61,499	18.93%	0	0.00%	4,707	1.45%	4,987	1.53%	57,920	18.00%	1,279	0.39%	4,196	1.29%	0	0.00%	0	0.00%
#2 Low Density Lipoprotein Control	301,578	233,253	77.34%	233,835	54,795	18.17%	0	0.00%	4,264	1.41%	6,863	2.28%	51,586	17.00%	1,245	0.41%	4,290	1.42%	0	0.00%	0	0.00%
#3 High Blood Pressure Control	343,935	237,389	69.02%	244,532	71,272	20.72%	0	0.00%	4,529	1.32%	20,661	6.01%	67,669	20.00%	1,373	0.40%	6,222	1.81%	0	0.00%	0	0.00%
#18 Diabetic Retinopathy: Documentation of Presence or Absence of	189,351	156,621	82.71%	156,660	,	0.00%	0	0.00%	3.149	1.66%	27,897	14.73%	735	0.00%	708	0.37%	1,101	0.58%	12	0.01%	0	0.00%
	100,001	100,021	02.7170	150,000	Ū	0.0070	·	0.0070	0,140	1.0070	21,031	14.7370	733	0.0070	700	0.57 70	1,101	0.3070	12	0.0170	Ü	0.0070
#19 Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care	131.566	75 046	57 04%	98 633		0.00%		0.00%	1.971	1.50%	29 616	22 51%	680	1.00%	465	0.35%	1.245	0.95%	0	0.00%	0	0.00%
#117 Dilated Eye Exam in Diabetic Patient	344,350	218,672	63.50%	219,506	114,456	0.00,0	0	0.00%	4,286	1.24%	4,570	1.33%	109,530	32.00%	1,272	0.37%	5,285	1.53%	3	0.00%	1	0.00%
	344,330	210,072	03.30 /0	219,300	114,430	33.2470	- 0	0.0076	4,200	1.24 /0	4,570	1.3376	109,550	32.00%	1,212	0.37 /6	5,265	1.55/6	3	0.00 /6		0.00%
#119 Urine Screening for Microalbumin or Medical Attention for	59,094	45.630	77.22%	45,647	10,554	17.86%		0.00%	783	1.33%	1.645	2.78%	9,047	15.00%	384	0.65%	1,668	2.82%	0	0.00%	0	0.00%
Nephropathy in Diabetic Patients	39,094	40,000	11.22/0	40,047	10,554	17.0070	- 0	0.0076	703	1.55%	1,045	2.1070	9,047	15.00 /6	304	0.00 /6	1,000	2.02/0	0	0.00 /6	U	0.00%
#126 Diabetic Foot and Ankle Care, Peripheral Neuropathy: Neurological Evaluation	66.402	58.641	88.31%	58.641		0.00%		0.00%	945	1.42%	6.069	9.14%	226	0.00%	475	0.72%	358	0.54%	0	0.00%	2	0.00%
	00,402	30,041	00.3170	30,041	U	0.0076	U	0.0076	540	1.42 /0	0,009	9.1470	220	0.00%	4/5	0.7270	330	0.3476	U	0.00 /6		0.00%
#127 Diabetic Foot and Ankle Care, Ulcer Prevention: Evaluation of Footwear	49,300	45,708	92.71%	45,708		0.00%		0.00%	721	1.46%	2,198	4.46%	216	0.00%	410	0.83%	197	0.40%		0.00%		0.00%
	49,300 63,081		64.99%	45,706	47.404		0		3,357					23.00%			2,890		0		1	0.00%
#163 Diabetes Mellitus: Foot Exam	03,061	40,999	04.99%	41,014	17,191	27.25%	U	0.00%	3,357	5.32%	817	1.30%	14,561	23.00%	547	0.87%	2,090	4.58%	U	0.00%	U	0.00%
Elder Care																						
#181 Elder Maltreatment Screen and Follow-Up Plan	1,062	528	49.72%	528	68	6.40%	0	0.00%	493	46.42%	0	0.00%	0	0.00%	41	3.86%	0	0.00%	0	0.00%	0	0.00%
End Stage Renal Disease (ESRD)																						
#79 Influenza Vaccination in Patients with ESRD	15,573	8,688	55.79%	8,688	0	0.00%	0	0.00%	148	0.95%	5	0.03%	5,747	37.00%	21	0.13%	964	6.19%	0	0.00%	0	0.00%
	.,	.,		5,100																	1	
#175 Pediatric End Stage Renal Disease (ESRD): Influenza Immunization	0	0	Ι.	0	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%
Endarterectomy								0.000		0.0010				0.007.0		0.00.0		0.0070		0.00.0		
,																						
#158 Endarterectomy: Use of Patch During Conventional Endarterectomy	1,651	1,497	90.67%	1,497	0	0.00%	0	0.00%	144	8.72%	0	0.00%	0	0.00%	10	0.61%	0	0.00%	0	0.00%	0	0.00%
Endoscopy and Polyp Surveillance	1,001	1,101	00.07 70	1,101	ŭ	0.0070	·	0.0070		0.7270	ŭ	0.0070	ŭ	0.0070	.0	0.0170	Ü	0.0070	Ū	0.0070	ŭ	0.0070
Endoscopy and Folyp Surveillance																						
#185 Endoscopy & Polyp Surveillance: Colonoscopy Interval for Patients																						
with a History of Adenomatous Polyps - Avoidance of Inappropriate Use	13.983	12,231	87.47%	12,231		0.00%		0.00%	623	4.46%	405	2 90%	543	4.00%	117	0.84%	128	0.92%		0.00%	0	0.00%
Falls	13,303	12,231	07.47%	12,231	U	0.0076	U	0.00%	023	4.40%	405	2.90%	543	4.00%	117	0.64%	120	0.92%	U	0.00 %	U	0.00%
i dio	202,503	156,980	77.52%	180,142	16 128	7.96%	0	0.00%	19,403	9.58%	0	0.00%	0	0.00%	2,958	1.46%	0	0.00%	0	0.00%	0	0.00%
#154 Falls: Risk Assessment	33,787	19,856	58.77%	19,857	10,120	0.00%		0.00%	19,403	0.00%	0	0.00%	0	0.00%	1,473	4.36%	0	0.00%	0	0.00%	0	0.00%
#155 Falls: Plan of Care	33,767	19,000	36.77%	19,007	U	0.00%	U	0.00%	U	0.00%	U	0.00%	U	0.00%	1,473	4.30%	U	0.00%	U	0.00%	U	0.00%
Glaucoma	055.040	504.000	70.040/	504 700		0.000/		0.000/	0.040	0.070/	440.044	40.000/	0.400	0.000/	4 400	0.000/	4.005	0.740/		0.000/		0.000/
#12 Optic Nerve Evaluation	655,816	524,262	79.94%	524,788	U	0.00%	- 0	0.00%	6,343	0.97%	119,341	18.20%	3,126	0.00%	1,438	0.22%	4,635	0.71%	2	0.00%	U	0.00%
#141 Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular																						
Pressure (IOP) by 15% OR Documentation of a Plan of Care					_		_												_		_	
	142,405	118,981	83.55%	127,366	U	0.00%	0	0.00%	1,560	1.10%	12,723	8.93%	327	0.00%	369	0.26%	375	0.26%	0	0.00%	0	0.00%
Hemodialysis Vascular Access Decision																						
#172 Hemodialysis Vascular Access Decision-Making by Surgeon to																						
Maximize Placement of Autogenous Arterial Venous (AV) Fistula	1,554	1,408	90.60%	1,408	2	0.13%	0	0.00%	66	4.25%	62	3.99%	7	0.00%	10	0.64%	1	0.06%	0	0.00%	0	0.00%
Hepatitis C (HCV)																						
#84 Initial Hepatitis C RNA Testing	1,441	1,333	92.51%	1,361	0	0.00%		0.00%	26	1.80%	44	3.05%	6	0.00%	4	0.28%	5	0.35%	0	0.00%	0	0.00%
#85 Genotype Testing Prior to Therapy	1,533	1,392	90.80%	1,432	0	0.00%		0.00%	28	1.83%	58		5	0.00%	10	0.65%	8	0.52%	0	0.00%	0	0.00%
#86 Consideration for Antiviral Therapy	699	620	88.70%	620	0	0.00%	_	0.00%	10	1.43%	67		0	0.00%	2	0.29%	5	0.72%	0	0.00%	0	0.00%
#87 RNA Testing at Week 12 of Therapy	749	683	91.19%	689	0	0.00%	_	0.00%	17	2.27%	40	5.34%	0	0.00%	3	0.40%	6	0.80%	0	0.00%	0	0.00%
#89 Counseling Patients Regarding Use of Alcohol	1,008	868	86.11%	868	0	0.00%	0	0.00%	13	1.29%	111	11.01%	5	0.00%	8	0.79%	12	1.19%	0	0.00%	0	0.00%
#90 Counseling Patients Regarding Use of Contraception Prior to Starting			l	1									Т									
Antiviral Therapy	189	119	62.96%	125	0	0.00%	0	0.00%	4	2.12%	10	5.29%	36	19.00%	3	1.59%	14	7.41%	0	0.00%	0	0.00%
#183 Hepatitis C: Hepatitis A Vaccination in Patients with HCV	706	556	78.75%	557	0	0.00%	0	0.00%	6	0.85%	138	19.55%	3	0.00%	2	0.28%	4	0.57%	0	0.00%	0	0.00%
#184 Hepatitis C: Hepatitis B Vaccination in Patients with HCV	724	572	79.01%	572	0	0.00%	0	0.00%	6	0.83%	143	19.75%	1	0.00%	2	0.28%	2	0.28%	0	0.00%	0	0.00%
HIT																						
#124 HIT - Adoption/Use of EHRs	4,607,412	4,381,789	95.10%	4,381,789	0	0.00%	0	0.00%	195,591	4.25%	0	0.00%	0	0.00%	30,004	0.65%	0	0.00%	29	0.00%	3	0.00%
Imaging																						
#195 Stenosis Measurement in Carotid Imaging Studies	184,131	170,818	92.77%	171,462	0	0.00%	0	0.00%	11,559	6.28%	0	0.00%	0	0.00%	1,110	0.60%	0	0.00%	0	0.00%	0	0.00%
Imaging-Stroke	. ,	.,,,,,,		,,,,					71.75						, 1							
#10 CT or MRI Reports	177,278	150,144	84.69%	161,713	0	0.00%	0	0.00%	5,222	2.95%	8,038	4.53%	1,306	1.00%	894	0.50%	361	0.20%	0	0.00%	0	0.00%
Influenza	,=.0	,							-,		.,											
#110 Vaccination for Patients ≥ 50 Years Old	338,116	324,685	96.03%	324,685	5,724	1.69%	n	0.00%	11,184	3.31%	n	0.00%	n	0.00%	2,244	0.66%	n	0.00%	3	0.00%	n	0.00%
Ischemic Vascular Disease	223,110	52-1,005	55.5570	524,003	5,724		Ů	0.0070	,.04	0.0170	Ů	0.0070	- 0	0.0070	2,277	5.5576	Ü	0.0070	3	2.2070	Ü	0.0070
Control	77,696	71,026	91.42%	73,305	n	0.00%	n	0.00%	691	0.89%	3,269	4.21%	84	0.00%	288	0.37%	97	0.12%	n	0.00%	0	0.00%
#202 Ischemic Vascular Disease (IVD): Complete Lipid Profile	87,260	81,430	93.32%	81,430	1	0.00%	0	0.00%	812	0.89%	4,400	5.04%	208	0.00%	318	0.36%	414	0.12%	0	0.00%	0	0.00%
	67,200	01,430	93.32%	01,430	<u> </u>	0.00%	U	0.00%	012	0.53%	4,400	0.0476	200	0.00%	310	0.30%	414	U.+170	U	0.00%	U	0.00%
#203 Ischemic Vascular Disease (IVD): Low Density Lipoprotein (LDL-C)	52,753	49,749	94.31%	49,749		0.00%	_ ^	0.00%	417	0.79%	2,176	4.12%	AE	0.00%	299	0.57%	0.7	0.18%	_	0.00%	_	0.00%
Control	52,753	49,749	94.31%	49,749	1	0.00%	0	0.00%	417	0.79%	2,176	4.12%	45	0.00%	299	0.57%	97	U. 16%	0	0.00%	U	0.00%
#204 Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic	75,070	69.883	02.000/	69.883	_	0.00%		0.00%	843	4.400/	3.426	4.56%	248	0.00%	561	0.750	183	0.24%	_	0.00%	_	0.00%
7 III. III GIIDOIG	/5,070	69,883	93.09%	69,883	0	0.00%	0	0.00%	843	1.12%	3,426	4.56%	248	0.00%	561	0.75%	183	0.24%	0	0.00%	0	0.00%
Leukemia (CLL)	40.000	0.55	04.00**			0.000	_	0.000/		0.700		4 700		0.000		0.000	,,	0.400		0.00**		0.000
#70 Baseline Flow Cytometry	10,491	9,891	94.28%	9,891	0	0.00%	0	0.00%	73	0.70%	493	4.70%	6	0.00%	24	0.23%	11	0.10%	0	0.00%	0	0.00%
Macular Degeneration								0.555		,	,	0										
#14 Dilated Macular Examination	567,438	546,244	96.26%	546,552	601	0.11%	0	0.00%	6,516	1.15%	11,479	2.02%	1,106	0.00%	1,684	0.30%	429	0.08%	10	0.00%	0	0.00%
#140 Age-Related Macular Degeneration (AMD): Counseling on Antioxidant			l	1									Т									
Supplement	337,407	325,535	96.48%	327,429	288	0.09%	0	0.00%	3,426	1.02%	5,167	1.53%	481	0.00%	852	0.25%	169	0.05%	0	0.00%	0	0.00%

^a For each measure, the total # of instances where an TIN/NPI combination submitted a QDC for that measure.

The # O Occurrences where a value ver is not present.

Note: MCMP and PCP pilot program participants are excluded from these reports (based on the most recent pilot participant list from ORDI).

Note: Individuals participating in GPRO are excluded from these reports.

 $^{^{\}it b}$ For each measure, the # of instances where an TIN/NPI combination submitted a valid QDC for that measure.

The # of occurrences of ODC reporting where the ODC does not match the denominator requirements for the measure.

The # of occurrences of a ODC reporting where the ODC does not match the age requirements for the measure.

The # of occurrences of a ODC reporting where the ODC does not match the gender requirements for the measure.

The # of occurrences of a ODC reporting where the ODC does not match the gender requirements for the measure.

g The # of occurrences where a valid NPI is not present.

	QDC Submission Attempts									Denomi	inator Mism	natch°										
		Total Valid			Patien	Age	Patient	Gender						and HCPCS			Incorrect D	OX and Only				
	Total QDCs	QDCs		Total QDCs Reported	Mismatch ^d		Mism		Incorrect		Incorre		Inco	rrect	Only QDC			DC	Resubmitted QDCsf		Unattribute	
Topic Measure	Reported ^a	Reported ^b	% Valid	on Eligible Cases	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%
Myelodysplastic Syndrome (MDS) and Acute Leukemias																						
#67 Baseline Cytogenetic Testing Performed on Bone Marrow	11,059	10,313	93.25%	10,313	0	0.00%		0.00%	91	0.82%	620	5.61%	10	0.00%	25	0.23%	7	0.06%	0	0.00%	0	0.00%
#68 Documentation of Iron Stores in Patients Receiving Erythropoietin	7.440	6 654	89 76%	0.004	١.,	0.00%		0.000/		0.000/	333	4 49%	_	0.00%		0.15%		0.000/		0.00%		0.000/
Therapy Medication Management	7,413	6,654	89.76%	6,991	0	0.00%	(0.00%	71	0.96%	333	4.49%	7	0.00%	11	0.15%	6	0.08%	0	0.00%	0	0.00%
Medication Management #46 Medication Reconciliation: Reconciliation After Discharge from an								-														
Inpatient Facility	10,508	165	1.57%	305	759	7.22%		0.00%	1,837	17.48%	0	0.00%	0	0.00%	420	4.00%	0	0.00%	0	0.00%	0	0.00%
#130 Documentation of Current Medications	1,574,520	1,488,296	94.52%	1,488,296	9	0.00%	C	0.00%	73,574	4.67%	0	0.00%	0	0.00%	12,638	0.80%	0	0.00%	12	0.00%	4	0.00%
Mental Health																						
#134 Screening for Clinical Depression	11,462	7,045	61.46%	7,045	0	0.00%	(0.00%	3,347	29.20%	0	0.00%	0	0.00%	1,070	9.34%	0	0.00%	0	0.00%	0	0.00%
Myeloma #60 Torotocot with Birotocotocotoc	8,127	7,739	95.23%	7,739	0	0.00%		0.00%	68	0.84%	278	3.42%	10	0.00%	22	0.27%	2	0.04%	0	0.00%	0	0.00%
#69 Treatment with Bisphosphonates	0,127	1,139	93.23/6	1,139	U	0.0076		0.0076	00	0.0476	210	3.42 /6	10	0.00%	22	0.21 /6	3	0.0476	U	0.00 /8	U	0.00%
#28 Aspirin at Arrival	27,059	23,371	86.37%	23,376	0	0.00%	(0.00%	817	3.02%	2,632	9.73%	105	0.00%	81	0.30%	41	0.15%	0	0.00%	0	0.00%
Nuclear Medicine											,											
#147 Nuclear Medicine: Correlation with Existing Imaging Studies for All									,													
Patients Undergoing Bone Scintingraphy	60,887	59,329	97.44%	59,479	0	0.00%	(0.00%	1,151	1.89%	0	0.00%	0	0.00%	257	0.42%	0	0.00%	0	0.00%	0	0.00%
Obesity	000.000	250 225	OF 400/	050.005	_	0.0007		0.0004	44.004	4.400/	_	0.000		0.000/	4.044	0.0407		0.000/	_	0.000/		0.000/
#128 Universal Weight Screening and Follow-Up	262,920	250,285	95.19%	250,285	0	0.00%	(0.00%	11,021	4.19%	0	0.00%	0	0.00%	1,614	0.61%	0	0.00%	0	0.00%	0	0.00%
Oncology #156 Oncology: Radiation Dose Limits to Normal Tissues	985	723	73.40%	723	0	0.00%	,	0.00%	25	3.55%	155	15.74%	61	6.00%		0.81%	4	0.41%		0.00%	0	0.00%
#194 Oncology: Cancer Stage Documented	34,768	32.326	92.98%	32,342	0	0.00%	1	0.00%	273	0.79%	1.937		74	0.00%	119	0.81%	50		0	0.00%	0	0.00%
Osteoporosis	51,700	32,320	22.0070	02,042		2.00 /0		2.5078	2.0	3.7070	1,007	2.07 70	. 7	3.0070	.13	3.5176	30	3.1170		0.0070	Ů	5.0070
#24 Communication with the Physician Managing Ongoing Care Post-																						
Fracture	5,680	1,778	31.30%	1,778	47	0.83%	(0.00%	117	2.06%	1,687	29.70%	1,165	21.00%	33	0.58%	1,844	32.46%	0	0.00%	0	0.00%
#39 Screening or Therapy for Women Aged 65 Years and Older	209,120	192,416	92.01%	192,416	4,799	2.29%	6,336		13,188	6.31%	0	0.00%	0	0.00%	3,512	1.68%	0	0.00%	4	0.00%	0	0.00%
#40 Management Following Fracture	51,585	1,116	2.16%	1,116	442	0.86%		0.00%	42	0.08%	46,991	91.09%	2,131	4.00%	54	0.10%	5,148	9.98%	0	0.00%	0	0.00%
#41 Pharmacologic Therapy	41,649	31,843	76.46%	31,843	350	0.84%		0.00%	534	1.28%	7,977	19.15%	837	2.00%	248	0.60%	658	1.58%	U	0.00%	0	0.00%
Utits #91 AOE: Topical Therapy	1,717	1.632	95.05%	1,632	0	0.00%	,	0.00%	21	1.22%	44	2.56%	2	0.00%	17	0.99%	2	0.12%	0	0.00%	0	0.00%
#91 AOE: Topical Therapy #92 AOE: Pain Assessment	1,311	1,202	91.69%	1,032	0	0.00%		0.00%	0	0.00%	62	4.73%	5	0.00%	- 17	0.38%	10	0.76%	0	0.00%	0	0.00%
	1,011	1,202	31.0370	1,202	-	0.0070	_	0.0070		0.0070	02	4.7370		0.0070		0.5070	10	0.7070		0.0070	0	0.0070
#93 AOE: Systemic Antimicrobial Therapy – Avoidance of Inappropriate Use	1,121	1,074	95.81%	1,075	0	0.00%	0	0.00%	16	1.43%	23	2.05%	0	0.00%	6	0.54%	2	0.18%	0	0.00%	0	0.00%
#94 OME: Diagnostic Evaluation – Assessment of Tympanic Membrane									1													
Mobility	79	0	0.00%	0	79	100.00%	(0.00%	0	0.00%	0	0.00%	79	100.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%
Pain Management Control of Pain Management	450.000	405.007	70 700/	405.007		0.000/	_	0.000/	07.004	47.470/		0.000/		0.000/	6.098	0.000/		0.000/		0.000/		0.000/
#131 Assessment Prior to Initiation of Patient Treatment Perioperative	159,296	125,367	78.70%	125,367	0	0.00%		0.00%	27,831	17.47%	0	0.00%	U	0.00%	6,098	3.83%	0	0.00%	0	0.00%	0	0.00%
#20 Timing of Antibiotic Prophylaxis - Ordering Physician	1,523,275	111,866	7.34%	112,006	83	0.01%		0.00%	1,392,225	91.40%	0	0.00%	0	0.00%	19,041	1.25%	0	0.00%	3	0.00%	0	0.00%
#21 Selection of Prophylactic Antibiotic - First OR Second Generation	1,020,270	111,000	7.0170	112,000		0.0170		0.0070	1,002,220	01.1070		0.0070		0.0070	10,011	1.2070		0.0070		0.0070	-	0.0070
Cephalosporin	105,139	83,161	79.10%	83,161	12	0.01%	(0.00%	21,187	20.15%	0	0.00%	0	0.00%	791	0.75%	0	0.00%	0	0.00%	0	0.00%
#22 Discontinuation of Prophylactic Antibiotics (Non-Cardiac Procedures)									1													
	99,028	52,036 62,582	52.55%	69,862	6	0.01%		0.00%	28,213 16,259	28.49%	0	0.00%	0	0.00%	953	0.96%	0	0.00%	0	0.00%	0	0.00%
#23 VTE Prophylaxis	79,422 1,502,396	1,181,029	78.80% 78.61%	62,583	0	0.01%	_ '	0.00%	298 676	20.47%	0	0.00%	0	0.00%	578 8.924	0.73%	0	0.00%		0.00%	0	0.00%
#30 Timing of Prophylactic Antibiotics - Administering Physician #45 Discontinuation of Prophylactic Antibiotics	89.100	21.027	23.60%	1,194,796 26,666	5	0.01%		0.00%	60,797	19.88% 68.23%	0	0.00%	0	0.00%	1,637	1.84%	0	0.00%	2	0.00%	0	0.00%
Pharyngitis	00,100	21,021	20.0070	20,000	Ü	0.0170	,	0.0070	00,101	00.2070		0.0070	J	0.0070	1,007	1.0470		0.0070		0.00%	Ü	0.0070
#66 Appropriate Testing for Children with Pharyngitis	590	1	0.17%	1	588	99.66%	C	0.00%	0	0.00%	1	0.17%	579	98.00%	0	0.00%	9	1.53%	0	0.00%	0	0.00%
Pneumonia																						
#56 Vital Signs for Community-Acquired Bacterial Pneumonia	230,638	216,873	94.03%	216,879	4	0.00%		0.00%	6,600	2.86%	5,693	2.47%	597	0.00%	824	0.36%	67	0.03%	0	0.00%	1	0.00%
#57 Assessment of Oxygen Saturation for Community-Acquired Bacterial Pneumonia	252,487	241,019	95.46%	241,019	1	0.00%	,	0.00%	7,064	2.80%	3,264	1.29%	197	0.00%	902	0.36%	69	0.03%	_	0.00%	0	0.00%
#58 Assessment of Mental Status for Community-Acquired Bacterial	202,707	241,019	55.40/0	241,019	 	0.00 /0	—	0.0070	1,004	2.00/0	5,204	1.20/0	101	3.0070	302	3.50 /6	09	0.00/6	- ·	0.00 /0	U	3.00 /6
Pneumonia	227,023	217,571	95.84%	217,611	2	0.00%	(0.00%	6,416	2.83%	1,878	0.83%	282	0.00%	790	0.35%	63	0.03%	0	0.00%	0	0.00%
#59 Empiric Antibiotic for Community-Acquired Bacterial Pneumonia	154,953	148,531	95.86%	148,531	2	0.00%	(0.00%	4,353	2.81%	1,271	0.82%	99	0.00%	661	0.43%	50	0.03%	0	0.00%	0	0.00%
Pneumonia Pneumococcal																						
#111 Vaccination for Patients 65 years and Older	351,433	323,989	92.19%	324,238	13,588	3.87%		0.00%	24,332	6.92%	0	0.00%	0	0.00%	2,863	0.81%	0	0.00%	0	0.00%	0	0.00%
Preventive Care and Screening								\vdash														
#173 Preventive Care and Screening: Unhealthy Alcohol Use - Screening	77,824	75,532	97.05%	75,532	n	0.00%		0.00%	1,876	2.41%	n	0.00%	n	0.00%	416	0.53%	n	0.00%	n	0.00%	n	0.00%
Prostate Cancer	,521	70,002	27.0070	10,002		2.0070		2.3070	.,5.0	/0		2.00,0	J	5.0070	-10	3.5570		0.0070		2.2270	Ü	3.0070
#102 Inappropriate Use of Bone Scan for Staging Low-Risk Prostate																						
Cancer Patients	2,351	1,469	62.48%	1,523	0	0.00%		0.00%	709	30.16%	6	0.26%	72	3.00%	31	1.32%	10	0.43%	0	0.00%	0	0.00%
#104 Adjuvant Hormonal Therapy for High-Risk Prostate Cancer Patients	1,824	1.326	72.70%	1,372	_	0.00%		0.00%	388	21.27%		0.22%	9.4	2.00%	20	1.10%		0.33%		0.00%		0.00%
	1,824	1,326	12.10%	1,3/2	0	0.00%	<u> </u>	0.00%	388	21.27%	4	0.22%	34	2.00%	20	1.10%	ь	0.33%	- 0	0.00%	0	0.00%
#105 Three-dimensional Radiotherapy for Patients with Prostate Cancer	2,195	1,638	74.62%	1,688	0	0.00%		0.00%	425	19.36%	14	0.64%	31	1.00%	35	1.59%	2	0.09%	0	0.00%	0	0.00%
Radiology																						
#145 Radiology: Exposure Time Reported for Procedures Using																						
Fluoroscopy	330,941	311,513	94.13%	311,524	0	0.00%		0.00%	16,576	5.01%	0	0.00%	0	0.00%	2,841	0.86%	0	0.00%	0	0.00%	0	0.00%
#146 Radiology: Inappropriate Use of "Probably Benign" Assessment	668,546	647.628	96.87%	647,680	_	0.00%	,	0.00%	15,090	2.26%	104	0.02%	1.659	0.00%	3,747	0.56%	276	0.04%		0.00%	0	0.00%
Category in Mammography Screening	000,340	041,020	30.0176	047,000	U	0.00%		0.00%	10,090	2.20%	104	U.UZ /0	1,009	0.00%	3,141	0.00%	2/0	0.04%		0.00%	U	0.00%

^a For each measure, the total # of instances where an TIN/NPI combination submitted a QDC for that measure.

^b For each measure, the # of instances where an TIN/NPI combination submitted a valid QDC for that measure.

⁶The # of occurrences of ODC reporting where the ODC does not match the denominator requirements for the measure.

⁸The # of occurrences of a ODC reporting where the ODC does not match the age requirements for the measure.

⁸The # of occurrences of a ODC reporting where the ODC does not match the gender requirements for the measure.

⁸The # of occurrences of a ODC reporting where the ODC does not anoth the gender requirements for the measure.

^g The # of occurrences where a valid NPI is not present.

Note: MCMP and PGP pilot program participants are excluded from these reports (based on the most recent pilot participant list from ORDI).

Note: Individuals participating in GPRO are excluded from these reports.

	QDC Sub	omission Attempts								Denomi	nator Misi	natch°										
	Total QDCs	Total Valid QDCs		Total QDCs Reported	Patient Age Mismatch ^d		Patient Misma		Incorrect	HCPCS	Incorre	ct DX	Both DX and HCPCS Incorrect		Only QDC on Claim		Incorrect DX and Only QDC		Resubmitted QDCs ^f		Unattributed (No NPI) ⁹	
Topic Measure	Reported ^a	Reported ^b	% Valid	on Eligible Cases	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%
Stroke and Stroke Rehabilitation																						
#31 DVT Prophylaxis for Ischemic Stroke or Intracranial Hemorrhage	6,378	5,237	82.11%	5,237	(0.00%	0	0.00%	403	6.32%	498	7.81%	158	2.00%	66	1.03%	32	0.50%	0	0.00%	0	0.00%
#32 Discharged on Antiplatelet Therapy	8,592	7,375	85.84%	7,375	(0.00%	0	0.00%	475	5.53%	402	4.68%	143	2.00%	129	1.50%	74	0.86%	0	0.00%	0,	0.00%
#35 Screening for Dysphagia	4,233	2,721	64.28%	3,163	(0.00%	0	0.00%	275	6.50%	471	11.13%	297	7.00%	24	0.57%	9	0.21%	0	0.00%	0	0.00%
#36 Consideration of Rehabilitation Services	6,316	5,315	84.15%	5,327	(0.00%	0	0.00%	328	5.19%	457	7.24%	95	2.00%	87	1.38%	45	0.71%	0	0.00%	0	0.00%
Syncope																						
#55 ECG Performed for Syncope	658,561	143,363	21.77%	143,366	113,026	17.16%	0	0.00%	4,428	0.67%	382,866	58.14%	124,591	19.00%	492	0.07%	6,865	1.04%	0	0.00%	2	0.00%
Thoracic Surgery																						
#157 Thoracic Surgery: Recording of Clinical Stage for Lung Cancer and Esophageal Cancer Resection	8.301	132	1.59%	132		0.00%	0	0.00%	33	0.40%	21	0.25%	7.153	86.00%	4	0.05%	958	11.54%	0	0.00%	2	0.02%
Tobacco Use	0,301	102	1.5570	152		0.0070	Ū	0.0070	55	0.4070	21	0.2070	7,100	00.0070	7	0.0070	330	11.5470	Ü	0.00 /0		0.0270
#114 Inquiry Regarding Tobacco Use	1,389,039	1,220,911	87.90%	1,325,970	3	0.00%	0	0.00%	56,219	4.05%	0	0.00%	0	0.00%	6,850	0.49%	C	0.00%	0	0.00%	0	0.00%
#115 Advising Smokers to Quit	718,794	665,562	92.59%	687,243	(0.00%	0	0.00%	27,068	3.77%	0	0.00%	0	0.00%	4,481	0.62%	C	0.00%	2	0.00%	0	0.00%
Upper Respiratory Infection (URI)																						
#65 Appropriate Treatment for Children	402	1	0.25%	1	400	99.50%	0	0.00%	0	0.00%	1	0.25%	392	98.00%	0	0.00%	8	1.99%	0	0.00%	0	0.00%
Urinary Incontinence (UI)																						
#48 Assessment of Presence or Absence of UI in Women Aged 65 Years and Older	146,340	127,886	87.39%	127,888	5,512	3.77%	5,843	3.99%	13,730	9.38%	0	0.00%	0	0.00%	4,706	3.22%		0.00%	17	0.01%	0	0.00%
#49 Characterization of UI in Women Aged 65 Years and Older	37,183	26,300	70.73%	26,312	1,533	4.12%	1,275	3.43%	696	1.87%	6,122	16.46%	2,605	7.00%	220	0.59%	1,410	3.79%	1	0.00%	0	0.00%
#50 Plan of Care for UI in Women Aged 65 Years and Older	34,025	24,783	72.84%	24,791	1,373	4.04%	1,134	3.33%	685	2.01%	4,827	14.19%	2,229	7.00%	330	0.97%	1,340	3.94%	2	0.01%	0	0.00%
Wound Care																						
#186 Wound Care: Use of Compression System in Patients with Venous Ulcers	785	288	36.69%	288	(0.00%	0	0.00%	52	6.62%	202	25.73%	10	1.00%	20	2.55%	29	3.69%	0	0.00%	0	0.00%
Total	23,965,173	19,271,071	80.41%	19,558,048	606,562	2.53%	16,115	0.07%	2,634,510	10.99%	1,013,937	4.23%	524,192	2.00%	165,801	0.69%	66,129	0.28%	124	0.00%	27	0.00%

^a For each measure, the total # of instances where an TIN/NPI combination submitted a QDC for that measure.

Note: MCMP and PGP pilot program participants are excluded from these reports (based on the most recent pilot participant list from ORDI). Note: Individuals participating in GPRO are excluded from these reports.

^b For each measure, the # of instances where an TIN/NPI combination submitted a valid QDC for that measure.

^cThe # of occurrences of QDC reporting where the QDC does not match the denominator requirements for the measure.

The # of occurrences of a QDC reporting where the QDC does not match the gender requirements for the measure.

The # of occurrences of a QDC reporting where the QDC does not match the gender requirements for the measure.

The # of occurrences of a QDC reporting where the QDC was received on a claim that was resubmitted for the purpose of adding QDCs.

g The # of occurrences where a valid NPI is not present.